Nanoform Q3 and 9M 2022 report: Continued solid progress
Company Announcement Nanoform Finland Plc November 29, 2022 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform Q3 and 9M 2022 report: Continued solid progress Highly promising in-vivo data for the treatment of glioblastoma multiforme presented with TargTex, new collaboration agreement signed with European consortium, first runs completed on both GMP line 2 and Biologics pilot line for GMP, work to find a manufacturing site in the US progressed well, while macroeconomic turbulence now present in talks with some smaller biotech companies. Q3 revenue growth of 79%